
CTOR — Citius Oncology, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$0.75
-$0.01 (-1.73%)
Citius Oncology, Inc. (CTOR) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Leonard L. Mazur, based in 420 Lexington Avenue, New York, NY, United States, 10170. Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Net income was -$5.4M. CTOR currently screens at market cap $105.2M.
Use this CTOR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CTOR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CTOR SEC filings page. Lician reads the product cache first so this HTML stays unique to Citius Oncology, Inc. even when a live quote feed is slow.
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
CTOR Key Statistics
Market Cap
$105.18M
Volume
16,521
Previous Close
$0.74
Day Range
$0.72 – $0.76
EPS
-$0.31
Revenue
$0.00
Net Income
-$21.15M
Gross Profit
$0.00
Free Cash Flow
$0.00
CTOR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$21.15M | $2.42M | $380.81K |
| EPS (Diluted) | -$0.31 | $0.27 | $0.12 |
Total Assets
$84.37M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$112.00
Operating Cash Flow
$126.35K
Free Cash Flow
$0.00
Citius Oncology, Inc. Company Information
- Chairman, CEO & President
- Leonard L. Mazur
- Headquarters
- 420 Lexington Avenue, New York, NY, United States, 10170
- Phone
- 347-627-0058
- IPO / Founded
- 2022-12-08
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic